
Curis (CRIS) Stock Forecast & Price Target
Curis (CRIS) Analyst Ratings
Bulls say
Curis is positioned for success with its promising pipeline and financial stability. Its recent positive results and expanded readouts in the TakeAim CLL and PCNSL studies demonstrate the efficacy and potential of its therapies. With a strong financial position and ongoing partnerships and collaborations, Curis has the resources and support to continue its development efforts and drive value for shareholders.
Bears say
Curis is a biotechnology company with a negative outlook, as its pipeline products have not shown strong results in the past and the company will likely need additional funding to continue development. Additionally, the current valuation is based on optimistic assumptions and the stock faces risks from potential failures in clinical trials. The company's financials may also be impacted by the need for substantial additional capital.
This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.
Curis (CRIS) Analyst Forecast & Price Prediction
Start investing in Curis (CRIS)
Order type
Buy in
Order amount
Est. shares
0 shares